This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded with Chiesi Inc.
Reference
Jensen IS, et al. Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. American Journal of Cardiovascular Drugs : 31 Jul 2021. Available from: URL: http://doi.org/10.1007/s40256-021-00491-9
Rights and permissions
About this article
Cite this article
Cangrelor appears to be cost effective in high-risk patients undergoing PCI in the USA. PharmacoEcon Outcomes News 884, 5 (2021). https://doi.org/10.1007/s40274-021-7912-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7912-8